The Mass Spectrometry society of Japan - The 68th Annual Conference on Mass Spectrometry, Japan
Japanese

Abstract

Table of contents

Timetable

Plenary Lectures

Society Featured Lecture

Oral Sessions (Day1, Day2, Day3)

Poster Presentations (Day3)

Workshops

Lunchtime Seminars (Day1, Day2, Day3)

Poster Presentations

Day 3, May 21（Fri.）　　Room P2 (Zoom)

3P-41　　PDF

Plasma Amyloid-β Biomarker Performance using MALDI-TOF MS with the Automated Immunoprecipitation

(1Shimadzu, 2NCGG)
oNaoki Kaneko1, Akinori Nakamura2, Ritsuko Yoda1, Takashi Kato2, Sadanori Sekiya1, Kengo Ito2, Shinichi Iwamoto1, Katsuhiko Yanagisawa2, Koichi Tanaka1

Abnormal amyloid-β (Aβ) deposition in the brain has been defined as the earliest pathological change of Alzheimer disease (AD). Using immunoprecipitation (IP) combined with MALDI-TOF MS, we have previously reported that the composite biomarker, which is a combination of APP669-711/Aβ1-42 ratio and Aβ1-40/ Aβ1-42 ratio in human plasma, correlates with amyloid PET status. In this study, we constructed an automated IP system for high-throughput analysis and then evaluated the biomarker performance by measuring 41 Aβ+ and 55 Aβ- subjects classified using PET with PIB tracer. In a receiver operating characteristic (ROC) analysis, MALDI-TOF MS with the automated IP showed high area under the ROC curves and accuracy in the three biomarkers.